Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
In the latest session, Lexeo Therapeutics Inc (NASDAQ: LXEO) closed at $10.44 down -1.79% from its previous closing price of $10.63. In other words, the price has decreased by -$1.79 from its previous closing price. On the day, 0.76 million shares were traded. LXEO stock price reached its highest trading level at $10.99 during the session, while it also had its lowest trading level at $10.32.
Ratios:
For a deeper understanding of Lexeo Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.40 and its Current Ratio is at 7.40. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.05.
Upgrades & Downgrades
In the most recent recommendation for this company, Raymond James on December 18, 2025, initiated with a Strong Buy rating and assigned the stock a target price of $25. On November 20, 2025, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $19. On October 15, 2025, Guggenheim started tracking the stock assigning a Buy rating and target price of $30.Guggenheim initiated its Buy rating on October 15, 2025, with a $30 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Nov 18 ’25 when Townsend Richard Nolan sold 1,127 shares for $9.27 per share. The transaction valued at 10,447 led to the insider holds 240,991 shares of the business.
Adler Eric sold 615 shares of LXEO for $5,701 on Nov 18 ’25. The Chief Medical Officer now owns 72,646 shares after completing the transaction at $9.27 per share. On Nov 18 ’25, another insider, See Tai Sandi, who serves as the Chief Development Officer of the company, sold 386 shares for $9.27 each. As a result, the insider received 3,578 and left with 65,476 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LXEO now has a Market Capitalization of 761987648 and an Enterprise Value of 647680704.
Stock Price History:
The Beta on a monthly basis for LXEO is 1.73, which has changed by 0.56784666 over the last 52 weeks, in comparison to a change of 0.13927746 over the same period for the S&P500. Over the past 52 weeks, LXEO has reached a high of $10.90, while it has fallen to a 52-week low of $1.45. The 50-Day Moving Average of the stock is 12.06%, while the 200-Day Moving Average is calculated to be 90.35%.
Shares Statistics:
For the past three months, LXEO has traded an average of 1.49M shares per day and 2120480 over the past ten days. A total of 72.99M shares are outstanding, with a floating share count of 60.28M. Insiders hold about 17.40% of the company’s shares, while institutions hold 77.27% stake in the company. Shares short for LXEO as of 1764288000 were 6037215 with a Short Ratio of 4.05, compared to 1761868800 on 5183029. Therefore, it implies a Short% of Shares Outstanding of 6037215 and a Short% of Float of 8.85.
Earnings Estimates
The stock of Lexeo Therapeutics Inc (LXEO) is currently drawing attention from 8.0 analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is -$0.34, with high estimates of -$0.25 and low estimates of -$0.43.
Analysts are recommending an EPS of between -$1.68 and -$2.26 for the fiscal current year, implying an average EPS of -$1.92. EPS for the following year is -$1.47, with 9.0 analysts recommending between -$1.03 and -$2.36.
